Fmr LLC Increases Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Fmr LLC lifted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 22.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,423 shares of the specialty pharmaceutical company’s stock after buying an additional 12,397 shares during the quarter. Fmr LLC owned approximately 0.15% of KalVista Pharmaceuticals worth $769,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Great Point Partners LLC bought a new stake in KalVista Pharmaceuticals during the second quarter worth about $15,768,000. Emerald Advisers LLC lifted its holdings in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after purchasing an additional 192,091 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in shares of KalVista Pharmaceuticals by 23.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after purchasing an additional 121,615 shares in the last quarter. Citigroup Inc. grew its stake in shares of KalVista Pharmaceuticals by 6.8% in the 3rd quarter. Citigroup Inc. now owns 305,504 shares of the specialty pharmaceutical company’s stock worth $3,538,000 after buying an additional 19,440 shares during the last quarter. Finally, Nicholas Investment Partners LP grew its stake in shares of KalVista Pharmaceuticals by 0.9% in the 2nd quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock worth $2,172,000 after buying an additional 1,714 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have issued reports on KALV. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th.

KalVista Pharmaceuticals Trading Down 3.4 %

KALV stock opened at $8.65 on Wednesday. The stock’s 50 day simple moving average is $10.60 and its 200 day simple moving average is $11.73. KalVista Pharmaceuticals, Inc. has a 12-month low of $8.48 and a 12-month high of $16.88. The stock has a market capitalization of $427.47 million, a PE ratio of -2.38 and a beta of 0.85.

Insider Activity

In other news, CEO Benjamin L. Palleiko sold 7,627 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the completion of the transaction, the chief executive officer now directly owns 274,596 shares of the company’s stock, valued at $2,677,311. The trade was a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,291 shares of company stock valued at $304,086 over the last ninety days. 10.50% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).